M.D. Anderson Cancer Center: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 29 Squamous Cell Carcinoma of Head and Neck studies with M.D. Anderson Cancer Center as lead sponsor. 4 are open to participants now and 10 have results posted.

Early Phase 1 3Phase 1 7Phase 2 19Phase 3 1Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.RecruitingNCT06162377Phase 4
• 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized TrialRecruitingNCT05674396Phase 2
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsRecruitingNCT05039801Phase 1
• Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal CancerRecruitingNCT03114462Phase 1
• Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaTerminatedNCT06046482Phase 2Results posted
• Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerCompletedNCT04555837Phase 1/2Results posted
• Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell CancerTerminatedNCT04220775Phase 1/2Results posted
• Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal CancerActive, not recruitingNCT04030455Phase 2Results posted
• Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaTerminatedNCT03799445Phase 2Results posted
• Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function MutationsTerminatedNCT03740100Phase 2Results posted
• Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical ResectionCompletedNCT01927744Phase 2Results posted
• Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and NeckCompletedNCT01064479Phase 2Results posted
• Preoperative Treatment With Cetuximab and/or IMC-A12CompletedNCT00957853Phase 2Results posted
• OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell CancerCompletedNCT00076310Phase 2Results posted
• Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT05845307Early Phase 1
• Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Active, not recruitingNCT05681039Phase 2
• Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT05668949Phase 1/2
• A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell CarcinomaTerminatedNCT05322135Early Phase 1
• Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck CancerCompletedNCT04870840Phase 1
• NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell CancerTerminatedNCT04862455Phase 2
• Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell CancerWithdrawnNCT04834349Phase 2
• Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal DiseaseCompletedNCT03868020Early Phase 1
• Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell CancerCompletedNCT03575949Not applicable
• Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal CancerActive, not recruitingNCT03224000Phase 2
• Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell CancerCompletedNCT03144778Phase 1
• Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal CancerActive, not recruitingNCT01893307Phase 3
• Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT01427205Phase 2
• Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT01154920Phase 2
• Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerActive, not recruitingNCT00494182Phase 2